We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

1 hedge funds and large institutions have $1K invested in POINT Biopharma Global Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

18,472% more call options, than puts

Call options by funds: $8.54M | Put options by funds: $46K

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 124

99% less funds holding

Funds holding: 125 → 1 (-124)

100% less capital invested

Capital invested by funds: $411M → $1K (-$411M)

Holders
1
Holders Change
-124
Holders Change %
-99.2%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
124
Calls
$8.54M
Puts
$46K
Net Calls
+$8.5M
Net Calls Change
+$9.58M

Top Buyers

Rank Fund Capital Flow
1
BTI
Blue Trust Inc
Georgia
+$1.65K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$70.5M
2
BlackRock
BlackRock
New York
-$44.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$31.1M
4
State Street
State Street
Massachusetts
-$23.5M
5
GPP
Great Point Partners
Connecticut
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
BTI
1
Blue Trust Inc
Georgia
$1K +$1.65K +127 New
BI
2
BVF Inc
California
– -$70.5M -10,563,748 Closed
BlackRock
3
BlackRock
New York
– -$44.3M -6,635,892 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$31.1M -4,667,786 Closed
State Street
5
State Street
Massachusetts
– -$23.5M -3,527,235 Closed
GPP
6
Great Point Partners
Connecticut
– -$19.4M -2,909,960 Closed
DTC
7
Deep Track Capital
Connecticut
– -$18.6M -2,781,565 Closed
BC
8
Boxer Capital
California
– -$16.7M -2,500,000 Closed
BG
9
Bellevue Group
Switzerland
– -$15.7M -2,351,160 Closed
Citadel Advisors
10
Citadel Advisors
Florida
– -$14.4M -2,157,166 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$12.7M -1,900,074 Closed
PHS
12
PFM Health Sciences
California
– -$10.8M -1,613,516 Closed
Thrivent Financial for Lutherans
13
Thrivent Financial for Lutherans
Minnesota
– -$7.38M -1,106,042 Closed
JJ
14
Johnson & Johnson
New Jersey
– -$6.67M -1,000,000 Closed
N
15
Nuveen
North Carolina
– -$6.64M -995,217 Closed
SFM
16
Sphera Funds Management
Israel
– -$6.35M -952,642 Closed
Millennium Management
17
Millennium Management
New York
– -$5.68M -851,735 Closed
Northern Trust
18
Northern Trust
Illinois
– -$5.48M -822,026 Closed
American Century Companies
19
American Century Companies
Missouri
– -$5.3M -794,611 Closed
Point72 Asset Management
20
Point72 Asset Management
Connecticut
– -$5.26M -789,100 Closed
OCAM
21
Onex Canada Asset Management
Ontario, Canada
– -$5.16M -772,905 Closed
PC
22
Pier Capital
Connecticut
– -$4.89M -732,936 Closed
Charles Schwab
23
Charles Schwab
California
– -$4.6M -689,179 Closed
JP Morgan Chase
24
JP Morgan Chase
New York
– -$4.05M -607,049 Closed
AQR Capital Management
25
AQR Capital Management
Connecticut
– -$3.69M -552,753 Closed
1
2 3 4 5

PNT Hedge Fund Activity: Q4 2023 in Review

1 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2023, worth a combined $1K — down 100% from $411M a quarter earlier.

Sellers outnumbered buyers: 124 funds closed out of PNT and 1 opened new positions — a net loss of 123 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Blue Trust Inc, opening a new position worth an estimated $1.65K. The largest seller was BVF Inc, exiting entirely with an estimated $70.5M sold.

  • 1 institutional investor held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2023, down from 125 in Q3 2023.
  • Funds reported $1K of POINT Biopharma Global Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 1 fund opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2023 and 124 closed out, a net change of -123 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2023 was Blue Trust Inc, an estimated $1.65K added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2023 was BVF Inc, an estimated $70.5M sold.

Based on aggregated 13F filings for Q4 2023.